( ate (ISR) and thecharacterization of t...)An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes,Health

After 24 weeks, the changes in static and dynamic beta cell responsiveness were increased across all active treatments relative to placebo, and appeared to be increased in an approximately additive fashion with co-administration with JANUVIA and high dose metformin compared to each as monotherapy. The results of the beta cell modeling analysis showed that the addition of JANUVIA to metformin resulted in a 49 percent increase in measured change in static beta cell responsiveness compared with metformin alone (20.1, JANUVIA 50 mg/metformin 1000 mg twice daily vs. 13.5, metformin 1000 mg twice daily). Further, the addition of JANUVIA to metformin resulted in a 114 percent increase in measured change in dynamic beta cell responsiveness compared with metformin alone (151.0, JANUVIA 50 mg/metformin 1000 mg twice daily vs. 70.7, metformin 1000 mg twice daily).

"These data further characterize the effects of DPP-4 inhibition and its role in combination with metformin, the most commonly prescribed drug for type 2 diabetes," said Luciano Rossetti, senior vice president and MRL head, Diabetes & Obesity and Cardiovascular Franchises, Merck & Co., Inc.

JANUVIA and metformin had a complementary effect to increase active GLP-1 concentrations in healthy adults (0286-OR; Study #050)

A randomized, placebo-controlled, double-blind, clinical pharmacology study was conducted in 16 healthy adults to assess the potential complementary effects of JANUVIA and metformin on GLP-1, an important incretin hormone. In each 2-day treatment period, subjects received one of four treatments: JANUVIA, metformin, the co-administration of JANUVIA and metformin, or placebo.

In this study, JANUVIA and metformin, when taken sepa
'"/>